Parameter | Median (meana) OS (95% CI) in months | 3-YSR | 5-YSR | Log-rank p | Median (meana) DFS (95% CI) in months | Log-rank p | Median (meana) HMFS (95% CI) in months | Log-rank p |
---|---|---|---|---|---|---|---|---|
Pt. on aspirin | *0.006 | *0.001 | *0.005 | |||||
Yes | 46.5a (35.6–57.4) | 61.1% | 61.1% | 26.0 (16.7–35.3) | 41.9a (30.3–53.4) | |||
No | 24.6a (20.2–28.9) | 26.3% | n/a | 10.5 (6.5–14.5) | 16.3 (11.4–21.1) | |||
Age | 0.405 | 0.348 | 0.957 | |||||
≤ Median | 26.5 (16.3–36.8) | 40.9% | 26.2% | 14.5 (8.2–20.8) | 17.9 (12.1–23.8) | |||
> Median | 24.9 (14.8–34.9) | 27.4% | n/a | 13.5 (11.2–15.8) | 21.5 (11.4–31.5) | |||
Sex | 0.555 | 0.856 | 0.949 | |||||
Female | 24.2 (16.2–32.2) | 29.2% | n/a | 13.9 (11.7–16.1) | 18.3 (7.3–29.4) | |||
Male | 27.1 (17.3–37.0) | 36.7% | 21.4% | 13.5 (8.5–18.5) | 19.7 (14.4–24.9) | |||
BMI | 0.127 | 0.601 | 0.956 | |||||
≤ Median | 35.0 (19.4–50.6) | 47.9% | 28.9% | 13.5 (6.7–20.3) | 19.6 (13.6–25.7) | |||
> Median | 21.0 (17.3–24.6) | 40.3% | 24.3% | 13.9 (10.5–17.3) | 17.7 (7.3–28.1) | |||
ASA score | 0.702 | 0.754 | 0.596 | |||||
ASA II | 26.5 (17.7–35.4) | 26.7% | n/a | 14.5 (10.9–18.1) | 14.5 (10.9–18.1) | |||
ASA III/IV | 22.3 (14.4–30.2) | 36.2% | 21.2% | 13.3 (9.7–16.9) | 20.9 (12.7–29.0) | |||
Platelet count | 0.598 | 0.720 | 0.616 | |||||
Normal | 24.2 (17.6–30.8) | 34.0% | n/a | 13.6 (11.0–16.2) | 17.9 (11.4–24.4) | |||
< 150 G/l | 21.0 (9.8–32.2) | n/a | n/a | 9.0 (7.8–10.2) | 23.9a (14.8–32.9) | |||
> 400 G/l | 37.8 (0–81.7) | 66,7% | n/a | 19.7 (0.8–38.6) | 19.7 (0.8–38.5) | |||
Serum CA19-9 | 0.092 | 0.128 | 0.196 | |||||
≤ Median | 29.1 (19.3–38.8) | 41.8% | n/a | 15.5 (12.3–18.7) | 26.0 (15.0–37.0) | |||
> Median | 18.9 (11.3–26.5) | 26.5% | 21.2% | 12.0 (7.0–17.0) | 18.3 (10.7–25.9) | |||
Type of resection | 0.314 | 0.995 | 0.999 | |||||
PD | 21.0 (17.7–24.2) | 29.4% | 21.5% | 12.8 (9.3–16.3) | 18.3 (9.2–27.4) | |||
DP | 37.1 (21.6–52.6) | 52.1% | n/a | 16.2 (14.7–17.7) | 20.9 (14.4–27.3) | |||
TP | 26.5 (22.4–30.7) | 30.0% | n/a | 14.5 (7.3–21.7) | 16.8 (12.1–21.4) | |||
Tumor diameter | 0.150 | 0.059 | *0.032 | |||||
≤ Median | 27.0 (17.4–36.6) | 41.7% | 37.1% | 13.9 (8.8–19.0) | 27.0 (17.6–36.4) | |||
> Median | 22.0 (13.4–30.6) | 28.2% | n/a | 12.8 (7.0–18.6) | 16.2 (12.9–19.4) | |||
T-stage | 0.352 | 0.249 | 0.402 | |||||
T1/2 | 37.8 (13.6–62.0) | 60.0% | 30.0% | 16.7 (12.5–20.9) | 19.7 (12.8–26.5) | |||
T3 | 24.2 (17.4–31.0) | 32.8% | n/a | 13.3 (10.3–16.3) | 17.9 (11.4–24.5) | |||
Nodal stage | 0.491 | 0.909 | 0.601 | |||||
N0 | 18.9 (13.9–23.9) | 25.2% | 25.2% | 12.5 (9.1–15.9) | 16.2 (8.1–24.2) | |||
N1 | 26.5 (21.2–31.8) | 39.5% | n/a | 13.6 (10.4–16.8) | 18.3 (11.8–24.8) | |||
ELN | 0.120 | 0.103 | 0.540 | |||||
≤ Median | 21.8 (15.7–27.9) | 28.6% | n/a | 12.8 (9.0–16.6) | 19.7 (14.3–25.0) | |||
> Median | 27.1 (15.6–38.6) | 40.6% | 34.8% | 14.9 (9.3–20.5) | 17.7 (2.8–32.6) | |||
Grading | 0.840 | 0.713 | 0.240 | |||||
G1/2 | 35.0 (9.3–60.8) | 41.0% | n/a | 16.2 (12.1–20.3) | 27.2 (12.4–41.9) | |||
G3 | 24.2 (18.3–30.1) | 32.9% | 24.0% | 12.5 (9.0–16.0) | 17.7 (11.6–23.8) | |||
Lymphovasc. invas | *0.039 | 0.095 | *0.049 | |||||
L0 | 27.4 (18.8–36.0) | 42.1% | 31.2% | 16.3 (13.8–18.8) | 26.0 (18.0–34.0) | |||
L1 | 18.9 (10.1–27.7) | 24.6% | n/a | 9.0 (7.2–10.8) | 13.9 (8.6–19.2) | |||
Vascular invasion | *0.039 | **< 0.001 | **< 0.001 | |||||
V0 | 27.0 (18.2–35.8) | 38.7% | 25.7% | 16.3 (12.4–20.2) | 24.9 (17.3–32.4) | |||
V1 | 14.4 (12.1–16.6) | 16.3% | n/a | 7.9 (6.4–9.4) | 9.0 (4.5–13.6) | |||
Perineural invasion | 0.424 | 0.153 | 0.216 | |||||
Pn0 | 35.0 (11.1–58.9) | 40.4% | 20.2% | 27.8 (11.9–43.7) | 32.7 (17.4–48.0) | |||
Pn1 | 24.2 (17.2–31.2) | 33.6% | n/a | 13.3 (10.3–16.3) | 17.7 (12.2–23.2) | |||
R-status | 0.366 | 0.756 | 0.225 | |||||
R0 wide | 26.5 (18.3–34.8) | 35.5% | 24.3% | 14.9 (11.2–18.6) | 21.5 (11.4–31.5) | |||
R0 narrow | 29.1 (15.8–42.3) | 39.6% | n/a | 13.9 (9.6–18.2) | 17.9 (9.6–26.3) | |||
R1 | 18.9 (6.0–31.8) | 26.7% | n/a | 12.0 (4.6–19.4) | 12.5 (1.2–23.7) | |||
Add. venous resect | 0.248 | 0.494 | 0.994 | |||||
Yes | 17.6 (6.0–29.1) | 25.0% | n/a | 12.5 (6.3–18.7) | 18.3 (9.3–27.4) | |||
No | 27.1 (19.0–35.2) | 38.7% | 22.7% | 13.9 (11.6–16.2) | 19.7 (12.7–26.6) | |||
Adjuvant therapy | 0.010 | 0.634 | 0.672 | |||||
Yes | 27.1 (14.2–40.1) | 43.1% | n/a | 15.5 (12.2–18.8) | 19.7 (12.3–27.0) | |||
No unknown | 12.4 (8.6–16.2) 19.3 (12.4–26.2) | n/a 26.9% | n/a 13.4% | 8.3 (7.5–9.1) 12.8 (8.3–17.3) | 21.5 (4.9–38.1) |